By Susanna Bachle
Read More
One of the biggest barriers to gene therapy treatment of central nervous system (CNS) diseases is the blood brain barrier (BBB). It’s the BBB’s job to block the entry of pathogens to the CNS, but this also stops viral vectors, such as adeno-associated virus (AAV), from reaching ...
Since rolling out our viral service in 2016, Addgene has shipped thousands of AAV and lentiviral preps to scientists around the world. In the years since, our scientists have optimized many steps in the viral production and quality control process to improve both the yield and ...
My lab's vector of choice is AAV, with nearly every experiment requiring AAV. Before joining my lab, I had never worked with AAV, so naturally I had to package some virus for my first experiment. It was a bit intimidating, but I had my lab’s protocols and some great co-workers ...
Background on neuronal tracing A key aspect to understanding the brain’s function is knowing its architecture, in particular the connections between different brain regions. For example, communication between the hippocampus and the prefrontal cortex brain regions is involved in ...
It was by serendipity that I got into the field of gene therapy, more specifically AAV-based retinal gene therapy. The year was 2001 and I started a job as a technician in a lab using adeno-associated viral vectors (AAVs) to treat an inherited retinal degenerative disease called ...
Guest blogger Todd Waldman, Professor at Georgetown University, contributed to this post. Adeno-associated viruses (AAVs) make fantastic gene delivery vehicles for episomal gene expression and are particularly useful for gene delivery to the nervous system. For many years they ...
Many of us take comfort in the fact that it’s often not quantity, but quality that really matters. Well, it turns out this isn’t the case for using AAV. When it comes to infecting cells, titer, the amount of virus used, really does matter. (*psst*, quality definitely also ...
